Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: Strategies for evading the humoral immune response

Human Gene Therapy

Volumn 7, Issue 5, 1996, Pages 619-626

  Rollins, Scott A ^a   Birks, Carl W ^a   Setter, Eva ^a   Squinto, Stephen P ^a   Rother, Russell P ^a  

^a ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C5; GALACTOSE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; BABOON; CELL STRAIN 3T3; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; CONTROLLED STUDY; DOG; EXPRESSION VECTOR; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIMATE; RABBIT; RETROVIRUS;

EID: 0029997197     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.5-619     Document Type: Article

References (58)

1. BARTHOLOMEW, R.M., ESSER, A.F., and MULLER-EBERHARD, H.J. (1978). Lysis of oncornaviruses by human serum: isolation of the viral complement (C1) receptor and identification as p15E. J. Exp. Med. 147, 844-853.
2. BARTHOLOMEW, R.M., and ESSER, A.F. (1980). Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes. Biochemistry 19, 2847-2853.
3. CARDOSO, J.E., BRANCHEREAU, S., JEYARAJ, P.R., HOUSSIN, D., DANOS, O., and HEARD, J.-M. (1993). In situ retrovirus-mediated gene transfer into dog liver. Hum. Gene Ther. 4, 411-418.
4. COOPER, N.R., JENSEN, F.C., RAYMOND, M.W., and OLDSTONE, M.B.A. (1976). Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144, 970-984.
5. CORNETTA, K., MOEN, R.C., CULVER, K., MORGAN, R.A., McLACHLIN, J.R., STURM, S., SELEGUE, J., LONDON, W., BLAESE, R.M., and ANDERSON, W.F. (1990). Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1, 15-30.
6. CULVER, K.W. (1994). Clinical applications of gene therapy for cancer. Clin. Chem. 40, 510-512.
7. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
8. DALMASSO, A.P., VERCELLOTTI, G.M., FISCHEL, R.J., BOLMAN, R.M., BACH, F.H., and PLATT, J.L. (1992). Mechanism of complement activation in the hyperactute rejection of porcine organs transplanted into primate recipients. Am. J. Pathol. 140, 1157-1168.
9. DUJARDIN, B.C.G., DRIEDIJK, P.C., ROIJERS, A.F.M., and OUT, T.A. (1985). The determination of the complement conponents C1q, C4 and C3 in serum and cerebrospinal fluid by radioimmunoassay. J. Immunol. Methods 80, 227-237.
10. FERRY, N., DUPLESSIS, O., HOUSSIN, D., DANOS, O., and HEARD, J.-M. (1991). Retroviral-mediated gene transfer into hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 88, 8377-8381.
11. GALILI, U. (1988). The natural anti-Gal antibody, the B-like antigen, and human red cell aging. Blood Cells 14, 205-220.
12. GALILI, U. (1993a). Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol. Today 14, 480-482.
13. GALILI, U. (1993b). Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody. Springer Semin. Immunopathol. 15, 155-171.
14. GALILI, U., RACHMILEWITZ, E.A., PELEG, A., and FLECHNER, I. (1984). A unique natural human IgG antibody with anti-α-galactosyl specificity. J. Exp. Med. 160, 1519-1531,
15. GALILI, U., MACHER, B.A., BUEHLER, J., and SHOHET, S.B. (1985). Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1-3)-linked galactose residues. J. Exp. Med. 162, 573-582.
16. GALILI, U., CLARK, M.R., SHOHET, S.B., BUEHLER, J., and MACHER, B.A. (1987). Evolutionary relationship between the natural anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 84, 1369-1373.
17. GALILI, U., SHOHET, S.B., KOBRIN, E., STULTS, C.L.M., and MACHER, B.A. (1988). Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263, 17755-17762.
18. Gene transfer clinical protocols for cancer therapy. (1994). Cancer Gene Ther. 1, 289-295.
19. GOOCHEE, C.F., GRAMER, M.J., ANDERSEN, D.C., BAHER, J.B., and RASMUSSEN, J.R. (1991). The oligosaccharides of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Biotechnology 9, 1347-1355.
20. HATZOGLOU, M., LAMERS, W., BOSCH, F., WYNSHAW-BORIS, A., CLAPP, D.W., and HANSON, R.W. (1990). Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase. J. Biol. Chem. 265, 17285-17293.
21. HUNG, G., KIRKMAN, E., SKOTZKO, M., GORDON, E.M., HEXDALL, L., FOLDI, J., DANEILS, J., PAREKH, D., ANDERSON, W.F., and STAIN, S. (1995). The safety of entrahepatic artery and inferior vena cava infusion of retroviral vector producer cells in pigs. J. Cell. Biochem. 21A, 408.
22. KENNEDY, S.P., ROLLINS, S.A., BURTON, W.V., SIMS, P.J., BOTHWELL, A.L.M., SQUINTO, S.P., and ZAVOICO, G.B. (1994). Protection of porcine aortic endothelial cells from complement-mediated cell lysis and activation by recombinant human CD59. Transplantation 57, 1494-1500.
23. KINGSTON, R.E., CHEN, C.A., and OKAYAMA, H. (1991). Transfection of DNA into eukaryotic cells. In Current Protocols in Molecular Biology I. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl, eds. (John Wiley & Sons, New York) pp. 9.1.1-9.1.9.
24. LEMISCHKA, I.R., RAULET, D.H., and MULLIGAN, R.C. (1986). Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45, 917-927.
25. MARKOWITZ, D., GOFF, S., and BANK, A. (1988). A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120-1124.
26. MARSCHANG, P., SODROSKI, J., WURZNER, R., and DIERICH, M.P. (1995). Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25, 285-290.
27. MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895-2902.
28. MOORMAN, D.W., BUTLER, D.A., STANLEY, J.D., LAMSAM, J.L., ACKERMANN, M.R., JACOBSON, C.D., and CULVER, K.W. (1994). Survival and toxicity of xenogeneic murine retroviral vector producer cells in liver. J. Surg. Oncol. 57, 152-156.
29. MORGAN, B.P., CAMPBELL, A.K., and COMPSTON, D.A.S. (1984). Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet 2, 251-254.
30. NEETHLING, F.A., KOREN, E., YE, Y., RICHARDS, S.V., KUJUNDZIC, M., ORIOL, R., and COOPER, D.K.C. (1994). Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by a-galactosyl oligosaccharides. Transplantation 57, 959-963.
31. OLDFIELD, E.H., and RAM, Z. (1995). Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. Hum. Gene Ther. 6, 55-85.
32. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., and DEVROOM, H.L. (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
33. PANDIT, L., HEGLAND, D., KWON, H., SKOTZKO, M., GORDON, E.M., ANDERSON, W.F., and PAREKH, D. (1995). In vitro transduction of GI tumor cells by a retroviral vector and survival of vector producer cells in the presence of human peritoneal fluid. J. Cell. Biochem. 21A, 426.
34. PETZ, L.D., SHARP, G.C., COOPER, N.R., and IRVIN, W.S. (1971). Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine 50, 259-275.
35. PLATT, J.L., VERCELLOTTI, G.M., DALMASSO, A.P., MATAS, A.J., BOLMAN, R.M., NAJARIAN, J.S., and BACH, F.H. (1990). Transplantation of discordant xenografts: a review of progress. Immunol. Today 11, 456-457.
36. RAFFEL, C., CULVER, K., KOHN, D., NELSON, M., SIEGEL, S., GILLIS, F., LINK, C.J., and VILLABLANCA, J.G. (1994). Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 863-890.
37. RAM, Z., CULVER, K.W., WALBRIDGE, S., BLAESE, R.M., and OLDFIELD, E.H. (1993a). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
38. RAM, Z., CULVER, K.W., WALBRIDGE, S., FRANK, J.A., BLAESE, R.M., and OLDFIELD, E.H. (1993b). Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurg. 79, 400-407.
39. RAM, Z., WALBRIDGE, S., HEISS, J.D., CULVER, K.W., BLAESE, R.M., and OLDFIELD, E.H. (1994a). In vivo transfer of the human interleukin-2 gene: Negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80, 535-540.
40. RAM, Z., WALBRIDGE, S., OSHIRO, E.M., VIOLA, J.J., CHIANG, Y., MUELLER, S.N., BLAESE, R.M., and OLDFIELD, E.H. (1994b). Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res. 54, 2141-2145.
41. RAM, Z., WALBRIDGE, S., SHAWKER, T., CULVER, K.W., BLAESE, R.M., and OLDFIELD, E.H. (1994c). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81, 256-260.
42. REPIK, P.M., STRIZKI, J.M., and GALILI, U. (1994). Differential host-dependent expression of α-galactosyl epitopes on viral glycoproteins: A study of eastern equine encephalitis virus as a model. J. Gen. Virol. 75, 1177-1181.
43. RETTINGER, S.D., PONDER, K.P., SAYLORS, R.L., DENNEDY, S.C., HAFENRICHTER, D.G., and FLYE, M.W. (1993). In vivo hepatocyte transduction with retrovirus during in-flow occlusion. J. Surg. Res. 54, 418-425.
44. ROTHER, R.P., ROLLINS, S.A., MENNONE, J., CHODERA, A., FIDEL, S.A., BESSLER, M., HILLMEN, P., and SQUINTO, S.P. (1994). Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. Blood 84, 2604-2611.
45. ROTHER, R.P., FODOR, W.L., SPRINGHORN, J.P., BIRKS, C.W., SETTER, E., SANDRIN, M.S., SQUINTO, S.P., and ROLLINS, S.A. (1995a). A novel mechanism of retrovirus inactivation in human serum mediated by anti-αgalactosyl natural antibody. J. Exp. Med. 182, 1345-1355.
46. ROTHER, R.P., SQUINTO, S.P., MASON, J.M., and ROLLINS, S.A. (1995b). Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther. 6, 429-435.
47. RUSSELL, D.W., BERGER, M.S., and MILLER, A.D. (1995). The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene. Ther. 6, 635-641.
48. SANDRIN, M.S., BAUGHAN, H.A., DABKOWSKI, P.L., and McKENZIE, I.F.C. (1993). Anti-pig IgM antibodies in human serum react predominantly with Gal(α1-3)Gal epitopes. Proc. Natl. Acad. Sci. USA 90, 11391-11395.
49. SPEAR, G.T., JIANG, H., SULLIVAN, B.L., GEWURZ, H., LANDAY, A.L., and LINT, T.F. (1991). Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res. Hum. Retroviruses 7, 579-585.
50. STANLEY, W.S., PETERS, B.P., BLAKE, D.A., YEP, D., CHU, E.H.Y., and GOLDSTEIN, I.J. (1979). Interaction of wild-type and variant mouse 3T3 cells with lectins from Bandeiraia simplicifolia seeds. Proc. Natl. Acad. Sci. USA 76, 303-307.
51. TAKAMIYA, Y., SHORT, M.P., MOOLTEN, F.L., FLEET, C., MINETA, T., BREAKEFIELD, X.O., and MARTUZA, R.L. (1993). An experimental model of retrovirus gene therapy for malignant brain tumors. J. Neurosurg. 79, 104-110.
52. TAKEUCHI, Y., COSSET, F.-L.C., LACHMANN, P.J., OKADA, H., WEISS, R.A., and COLLINS, M.K.L. (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001-8007.
53. TSURUOKA, T., TSUJI, T., NOJIRI, H., HOLMES, E.H., and HAKOMORI, S. (1993). Selection of a mutant cell line based on differential expression of glycosphingolipid, utilizing anti-lactosylceramide antibody and complement. J. Biol. Chem. 268, 2211-2216.
54. VAUGHAN, H.A., LOVELAND, B.E., and SANDRIN, M.S. (1994). Galα(1,3)gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 58, 879-882.
55. WIDNER, H., and BRUNDIN, P. (1988). Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res. Rev. 13, 287-324.
56. WILLIAMS, D.A., LEMISCHKA, I.R., NATHAN, D.G., and MULLIGAN, R.C. (1984). Introduction of a new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310, 476-480.
57. 4 isolated from Bandeiraea simplicifolia. Arch. Biochem. Biophys. 198, 1-9.
58. ZHAO, J., ROLLINS, S.A., MAHER, S.E., BOTHWELL, A.L.M., and SIMS, P.J. (1991). Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J. Biol. Chem. 266, 13418-13422.